Generic placeholder image

Recent Patents on Drug Delivery & Formulation

Author(s): Hetal Patel* and Mukesh Gohel

DOI: 10.2174/1872211313666190212115139

Cite As
A Review on Enteric Coated Pellets Composed of Core Pellets Prepared by Extrusion-Spheronization

Page: [83 - 90] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Enteric coated dosage form bypasses the stomach and releases the drug into the small intestine. Advantages of enteric coated pellets in comparison with enteric coated tablets are a) Pellets provide rapid onset of action and faster drug release due to the smaller size than tablets and b) Pellets exhibit less residence time of acid-labile drugs in the stomach compared to tablets. Dosage form coat can be damaged by longer resistance time in the stomach. The present review summarizes the current state of enteric coated pellets where core pellets are prepared by extrusion-spheronization technique and the enteric coating is applied in a fluidized bed processor. Two approaches are involved in the preparation of core pellets. In the first approach, a mixture of drug and excipient(s)/co-processed excipient is passed through extruders to prepare core pellets. In the second approach, excipient core pellets are prepared by extrusion technique and the drug is layered onto it before the enteric coating. The excipients present in the core pellets decide immediate or extended release of drug in the intestine. The coprocessed excipient pellets provide less batch variability and provide a platform for layering of many drugs before enteric coating. Some patents included enteric coating pellets [CN105456223 (A), CN105596310 (A), CN105616371 (A), CN105663095 (A), CN101611766B, CN106511862 (A), CN106668018 (A), CN106727381 (A), CN106924222 (A), TW200624127 (A), US 2017/0165248A1, US 2017/0224720A1] are discussed.

Keywords: Enteric, eudragit, coating, extrusion, spheronization, co-processed.

Graphical Abstract

[1]
Fox CB, Kim J, Le LV, et al. Micro/nanofabricated platforms for oral drug delivery cade. J Control Release 2016; 219: 431-44.
[2]
Musther H, Olivares-Morales A, Hatley O, Liu B, Rostami Hodjegan A. Animal versus human oral drug bioavailability: Do they correlate? Eur J Pharm Sci 2014; 57: 280-91.
[3]
Qiu Y, Lee P. In: Qiu Y, Chen Y, Zhang G, Yu L, Mantri R, Eds. Developing oral solid dosage forms pharmaceutical theory and practice. 2nd ed. United States: Mica Haley 2017: 519.
[4]
Ramu S, Reddy PCG, Rao DS, Ramakrishna G. Formulation and evaluation of lansoprazole delayed release pellets. Int J Pharm Chem Biol Sci 2015; 5: 860-78.
[5]
Joshi A. A review - Modified release drug delivery syatem and its significance. Curr Res Biol Pharm Sci 2014; 3: 1-6.
[6]
Agrawal S, Joshi K, Gaud R. Formulation development of Multi Unit Particulate System (MUPS) for anti-diabetic drugs. Asian J Pharm Sci 2016; 11: 77-8.
[7]
Wang J, Sun Y, Li B, Fan R, Li B, Yin T. Preparation and evaluation of tamsulosin hydrochloride sustained-release pellets modified by two-layered membrane techniques. Asian J Pharm Sci 2015; 10: 31-9.
[8]
Tirpude R, Puranik P. Rabeprazole sodium delayed-release multiparticulates: Effect of enteric coating layers on product performance. J Adv Pharm Technol Res 2011; 2: 184-91.
[9]
Samal HB, Debata J, Kumar NN, Sneha S, Kumar P. Formulation and evaluation of enteric coated pellets of omeprazole. Int J Drug Dev Res 2012; 4: 326-33.
[10]
Islam S, Khatun F, Bakr A, Mondal I, Haque M, Mahmud A. A review on biodegradable polymers for enteric coating material. Int J Pharm Pharm Res 2016; 6: 142-59.
[11]
Wilson B, Babubhai PP, Sajeev MS, Jenita JL. Sustained release enteric coated tablets of pantoprazole : Formulation, in vitro and in vivo evaluation. Acta Pharm 2013; 63: 131-40.
[12]
De Barros JM, Scherer T, Dimitrios C, Khutoryanskiy VV, Edwards AD. A laminated polymer film formulation for enteric delivery of live vaccine and probiotic bacteria. J Pharm Sci 2014; 103(7): 1-11.
[13]
Raval MK, Ramani RV, Sheth NR. Formulation and evaluation of sustained release enteric-coated pellets of budesonide for intestinal delivery. Int J Pharma Investig 2013; 3: 203-11.
[14]
Tummala S, Satishkimar M, Prakash A. Formulation and characterization of 5-Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharm J 2014; 23(3): 308-14.
[15]
Niranjan C, Priya R, Swain S, Kumar G, Charan K, Ghose D. Pharmaceutical significance of Eudragit : A review. Futur J Pharm Sci 2017; 3: 33-45.
[16]
Kanwar N, Kumar R, Sinha VR. Preparation and evaluation of multi-particulate system (pellets) of Prasugrel hydrochloride. Open Pharm Sci 2015; 2: 74-80.
[17]
Muley S, Nandgude T, Poddar S. Extrusion-spheronization a promising pelletization technique: In-depth review. Asian J Pharm Sci 2016; 11: 684-99.
[18]
Yadav N, Verma A. Pharmaceutical pellets: A versatile carrier for oral controlled delivery of drugs. Indian J Pharm Educ Re 2016; 50: 146-60.
[19]
Vervaet C, Baert L, Remon JP. Extrusion-spheronisation a literature review. Int J Pharm 1995; 116: 131-46.
[20]
Ghebre-Sellassie IKA. Pelletization technique. In: Swarbrick J, Ed. Encyclopedia of pharmaceutical technology. 3rd ed. New York: Informa health care; 2007: 2651-62.
[21]
Srivastava SMG. Fluid bed technology: Overview and parameters for process selection. Int J Pharm Sci Drug Res 2010; 2: 236-46.
[22]
Pu D, Li B, Xu J, et al. Mesalazine sustained-release pellets, preparation method thereof and mesalazine sustained-release capsule CN105456223A 2016.
[23]
Chengzhi Y, Yang K, Xiaobao S. Esomeprazole enteric-coated tablets and preparation method thereof CN105596310A (2016).
[24]
Guangli NA, Kede J, Liyun C, et al. Preparation technology of inhibition tablet used for treating acute gastric acid secretion CN105616371A (2016).
[25]
Mufeng X, Xuewei SCH, Jinyan L, et al. Preparation method of [R)- lansoprazole sustained-release capsule CN105663095A (2016).
[26]
Zhou L, Ye F. Production method of enteric-coated kitasamycin for feed CN101611766A (2009).
[27]
Labao C. Drug for treating inflammatory rheumatic diseases through combination of Chinese traditional and western medicine and preparation method for drug CN106511862A 2017.
[28]
Yusheng B, Tao M, Li X, et al. Sustained release capsule of sodium dexlansoprazole and preparation method thereof CN106668018A (2017).
[29]
Min T, Bao Y, Liu T, et al. Orally disintegrating tablet of [R)-Lansoprazole sodium and preparation method thereof CN106727381A (2017).
[30]
Zhuqing H. Preparation process of radix aucklandiae extract enteric coated pellets CN107595917A (2018).
[31]
Martin W, Peter W, Katrin W, Niclas LE. New modified release pellet formulations for proton pump inhibitors TW200624127A (2006).
[32]
Persson E, Persson T. Solid dosage form comprising proton pump inhibitor and suspension made thereof US2017/0165248A (2017).
[33]
Pergoran G, Nils OG, Nils OL, Jessica E. Oral cholestyramine formulation and use US2017/0224720A1 (2017).
[34]
Vamshi KT, Reddy MS. Formulation and evaluation ofenteric coated pellets of rifampicin and isoniazid with improved rifampicin stability. Asian J Pharm Clin Res 2014; 7: 1-3.
[35]
Lecomtea F, Siepmanna J, Waltherb M. Blends of enteric and GIT-insoluble polymers used for film coating: Physicochemical characterization and drug release patterns. J Control Release 2003; 89: 457-71.
[36]
Kilor VA, Sapkal NP, Awari JG, Shewale BD. Development and characterization of enteric-coated immediate-release pellets of aceclofenac by extrusion/spheronization technique using kappa-carrageenan as a pelletizing agent. AAPS PharmSciTech 2010; 11: 336-43.
[37]
Déo SC, Andreazza IF, Possamai JC. Development of mesalazine pellets coated with methacrylic-derived polymer. Braz J Pharm Sci 2011; 47: 103-9.
[38]
Dukic-Ott A, Beer T, Paul J, Baeyens W. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion / spheronisation. Eur J Pharm Biopharm 2008; 70: 302-12.
[39]
Goyanes A, Souto C, Martínez-Pacheco R. Co-processed MCC-Eudragit® excipients for extrusion-spheronization. Eur J Pharm Biopharm 2011; 79: 658-63.
[40]
Goyanes A, Martinez-Pacheco R. New co-processed MCC-based excipient for fast release of low solubility drugs from pellets prepared by extrusion-spheronization. Drug Dev Ind Pharm 2015; 41: 1-7.
[41]
Tho I, Arne S, Kleinebudde P. Pectinic acid, a novel excipient for production of pellets by extrusion / spheronisation : Preliminary studies. Eur J Pharm Biopharm 2002; 54: 95-9.
[42]
Tian L, Zhang Y, Tang X. Sustained-Release pellets prepared by combination of wax matrices and double-layer coatings for extremely water-soluble drugs. Drug Dev Ind Pharm 2008; 34(6): 569-76.
[43]
Kallai N, Luhn O, Dredan J, Kovacs K, Lengyel MAI. Evaluation of drug release from coated pellets based on isomalt, sugar, and microcrystalline cellulose inert cores. AAPS PharmSciTech 2010; 11: 383-91.
[44]
Patel H, Patel K, Tiwari S, Pandey S, Shah S, Gohel M. Quality by Design (QbD) approach for development of co-processed excipient pellets (MOMLETS) by extrusion-spheronization technique. Recent Pat Drug Deliv Formul 2016; 10: 1-15.